What do systematic reviews say?

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

The review found no eligible studies for this question.

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 8485 participants
  Moderate

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.94 [0.72, 1.23]
  4 studies · 1060 participants
  Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.34, 1.15]
  4 studies · 1050 participants
  Low